No abstract

Simvastatin and ezetimibe did not reduce the composite outcome of combined aortic-valve events and ischemic events in patients with aortic stenosis. Such therapy reduced the incidence of ischemic cardiovascular events but not events related to aortic-valve stenosis. (ClinicalTrials.gov number, NCT00092677.)

No abstract

ESPITE SUBSTANTIAL BENefits from lowering blood pressure (BP), conventional treatment does not normalize the risk of major cardiovascular (CV) events in patients with hypertension. 1-5 Progress has been made in predicting risk of hypertension by evaluating preclinical CV disease. 6 Left ventricular hypertrophy (LVH), ie, pathologically increased left ventricular mass, independently predicts adverse outcomes in diverse populations, 7-12 including patients with hypertension. 7,11 These findings suggest that the level of left ventricular mass and mass reduction during treatment of hypertension may provide independent information about disease progression or control. This hypothesis has been supported by data from some, 13,14 but not other, 15,16 electrocardiographic studies. Echocardio-See also pp 2343 and 2396 and Patient Page.